NICE diagnostic guidance (DG25) on high-throughput non-invasive prenatal testing for fetal RHD genotype recommended further research on the implementation and resource use of the of the technology.
The aim of this study was to evaluate the implementation of high-throughput NIPT for fetal RHD genotype in maternity units in England by addressing research recommendations from the NICE. These were to reduce uncertainty around the resource use and cost of staff training, management of samples and results and record-keeping, as well as resultant changes to antenatal or post-partum care and performance of NIPT.
Cedar developed a survey based on NICE’s research recommendations which was sent to clinicians at 39 NHS Trusts in England in May 2018. Topics which required further investigation were explored using qualitative interviews with 7 clinicians from a selection of sites. This work has been published here:
Ryczek, E., White, J., & Carolan‐Rees, G. (2020). Implementation of high‐throughput non‐invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross‐sectional survey of maternity units and expert interviews. Transfusion Medicine, 30(4), 287-294.